<DOC>
	<DOCNO>NCT00633464</DOCNO>
	<brief_summary>The purpose study estimate response rate ixabepilone monotherapy , combination ixabepilone plus cetuximab first-line treatment female subject triple negative ( estrogen receptor [ ER ] , progesterone receptor [ PR ] , Human Epidermal Growth Factor Receptor 2 [ HER2 ] negative ) locally advanced non-resectable and/or metastatic breast cancer</brief_summary>
	<brief_title>Randomized Phase II Study Ixabepilone Alone Ixabepilone Plus Cetuximab First-Line Treatment Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Female subject triple negative ( ER , PR , HER2 negative ) locally advance nonresectable and/or metastatic breast cancer Prior adjuvant neoadjuvant anthracyclinebased chemotherapy Tumors fluorescence situ hybridization test ( FISH ) positive immunohistochemistry ( IHC ) 3+ Neuropathy &gt; Grade 1 Prior systemic therapy metastatic disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>